AR and neoplasm: Preclinical evidence shows that the AR effect depends on tumor subtype: in estrogen receptor-positive cancer cells AR activity is able to inhibit tumor growth (10), whereas in TNBC AR seems to retain an oncogenic effect (11, 12).